This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Top ETF Stories of First Quarter
by Sanghamitra Saha
The first quarter of 2021 has been bestowed with upbeat news like the rollout of hefty fiscal stimulus in the United States, growing distribution of vaccines and the starting of the economic reopening while rising rate worries and tax hike fears were the dampeners.
5 Best-Performing Sector ETFs of Q1
by Sweta Killa
While many corners of the equity world witnessed an upside, a few sector ETFs performed incredibly, thereby comfortably crushing the broader markets.
5 ETF Winners of Coronavirus Pandemic
by Sweta Killa
It's been a year since the World Health Organization declared COVID-19 a pandemic, which brought the economy to a standstill and led to a crash in the stock markets.
5 Top-Performing ETFs of February
by Sanghamitra Saha
Though the start of February was upbeat, rising rate worries triggered a crash at month-end.
5 Best Sector ETFs of February
by Sweta Killa
The flight to cyclical sectors benefited the major bourses last month despite the sell-off in high-growth and high-beta stocks.
Should You Invest in Marijuana Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
6 Top-Performing ETFs of Last Week
by Sanghamitra Saha
Last week was marked by the bitcoin rally, some Reddit bets and uptrend in some cyclical sectors.
Marijuana ETFs on a High on Reddit Frenzy
by Sanghamitra Saha
After promoting GameStop (GME) and Silver, Reddit's discussion has now popularized marijuana stocks like Sundial Growers (up 78.8% on Feb 10) and Tilray (up more than 50% on Feb 10).
5 Small-Cap ETFs at the Forefront of the 2021 Market Rally
by Sweta Killa
We have presented five ETFs that are easily crushing the Russell 2000 Index this year and are likely to continue their strong performance at least in the near term.
Cannabis ETFs Spike on Jazz-GW Pharma Deal
by Sweta Killa
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.